ANDROGEN-DEPRIVATION THERAPYPLUS PREDNISONEOPEN-LABELPHASE-IIDOCETAXELSURVIVALTreatment for metastatic hormone-sensitive prostate cancer has undergone significant evolution in recent years, leading to substantial improvements in overall survival. Men are living longer than ever before with a median survival now...
Metastatic prostate cancer is considered to be incurable. But now a pilot trial, in 20 selected men with early-stage metastatic prostate cancer, has shown that aggressive multimodality treatment with hormone therapy, surgery, and radiation "can eliminate detectable disease." Overall, 20% of the ...
Alicia Morgans, M.D., MPH: Metastatic hormone-sensitive prostate cancer is a particular type or stage of prostate cancer in which the cancer has spread outside of the prostate—that's the metastatic term—and hormone-sensitive means that it hasn't yet been treated with androgen deprivation th...
luteinizing hormone; FSH, follicle-stimulating hormone; GnRH, gonadotropin-releasing hormone; AR, androgen receptor; CYP, cytochrome P450; RANKL, receptor activator of nuclear factor kappa-Β ligand; PD-1, programmed cell death protein 1; MSI-H, microsatellite instability-high; PCa, prostate cancer...
PostateCancerPCSMThe last five years has witnessed a remarkable evolution in the management of metastatic hormone-sensitive prostate cancer (mHSPC), with multiple agents demonstrating profound benefit in combination with initial androgen deprivation therapy (ADT). Historically, in a time when systemic ...
If you are taking LYNPARZA for prostate cancer and you are receiving gonadotropin-releasing hormone (GnRH) analog therapy, you should continue with this treatment during your treatment with LYNPARZA unless you have had a surgery to lower the amount of testosterone in your body (surgical castratio...
, if the prostate cancer has spread to the bones What are the treatment options for prostate cancer? Treatment for prostate cancer is determined based on the size of the tumor and extent of metastasis and may include the following: Hormone therapy ...
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387:1163–77. CAS PubMed PubMed Central Google Scholar Ratta R, ...
If you are taking LYNPARZA for prostate cancer and you are receiving gonadotropin-releasing hormone (GnRH) analog therapy, you should continue with this treatment during your treatment with LYNPARZA unless you have had a surgery to lower the amount of testosterone in your body (surgical castratio...
Re: Chemohormonal Therapy in Metastatic Hormone-sensitive Prostate Cancer To analyze the correlation between circulating tumor cell (CTC) levels and clinicopathologic parameters (prostate-specific antigen level, Gleason score, and TNM stage) in patients with metastatic hormone-sensitive prostate cancer (PCa...